
S1 Ep4: OT Roundup Ep. 4: 3 FDA approvals, Duravyu LUCIA miss, brepocitinib, GLP-1 and DME
Shownotes
This edition of OT Roundup covers 3 FDA approvals announced on a single day, a second phase 3 miss for Duravyu in wet age-related macular degeneration (AMD) with Veeral Sheth, MD, positive phase 3 results for brepocitinib in noninfectious uveitis, and registry data on GLP-1 receptor agonists and anti-VEGF treatment in diabetic macular edema (DME).